

059423.060401

- 1 1. A substantially pure mannin-binding lectin
2 associated serine protease-2 (MASP-2) polypeptide.
- 1 2. The polypeptide of claim 1, said polypeptide
2 being capable of associating with mannan-binding lectin
3 (MBL).
- 1 3. The polypeptide of claim 1, said polypeptide
2 being conjugated to a label or toxin.
- 1 4. A polypeptide containing the sequence
2 identified as SEQ ID NO. 1.
- 1 5. A polypeptide according to claim 4 with a
2 molecular mass of 20K.
- 1 6. A polypeptide with a molecular mass of 52K and
2 containing the sequence identified as SEQ ID NO 1.
- 1 7. The polypeptide of claim 1, said polypeptide
2 having serine protease activity.
- 1 8. A polypeptide of claim 1, said polypeptide being
2 capable of MASP-2 activity in an *in vitro* assay for MBLectin
3 complement pathway function.
- 1 9. A polypeptide according to claim 1, said
2 polypeptide being capable of competitively inhibiting MASP-2
3 serine protease activity.

1 19. An antibody that selectively binds to MASP-2.

1 20. The antibody of claim 18 or claim 19, wherein
2 said antibody is a monoclonal antibody.

1 21. The antibody of claim 18 or 19, said antibody
2 being coupled to a compound comprising a detectable marker.

546 a²
1 ~~22. A pharmaceutical composition comprising the~~
2 ~~polypeptide of claim 1 or the antibody of claims 18 or 19.~~

1 ~~23. A method for detecting mannin-binding lectin~~
2 ~~associated serine protease-2 (MASP-2), said method~~
3 ~~comprising:~~
4 ~~(a) obtaining a biological sample;~~
5 ~~(b) contacting said biological sample with a MASP-2~~
6 ~~polypeptide specific binding partner that specifically binds~~
7 ~~MASP-2; and~~
8 ~~(c) detecting said complexes, if any, as an~~
9 ~~indication of the presence of mannin-binding lectin~~
10 ~~associated serine protease-2 in said sample.~~

1 ~~24. A method according to claim 23, in which the~~
2 ~~specific binding partner is an antibody.~~

1 ~~25. A method for detecting MASP-2, said method~~
2 ~~comprising an assay for MASP-2 complement fixing activity.~~

1 ~~26. The methods of claims 23 or 24 for quantitative~~
2 ~~assay of MASP-2 or MASP-2 activity in biological samples.~~

1 27. A method for detecting MASP-2 nucleic acid
2 expression, comprising detecting RNA having a sequence
3 encoding a MASP-2 polypeptide by mixing the sample with a
4 nucleic acid probe that specifically hybridizes under
5 stringent conditions to the nucleic acid of claim 13 or 14.

1 28. A method for treating patients deficient in
2 MASP-2 by administering to the patient the peptide of claim
3 1.

1 29. A method for treating patients deficient in
2 MASP-2 by administering to the patient nucleic acid
3 according to claim 13 or 14.

1 30. A method for inhibiting the activity of MASP-2
2 by administering to the subject a compound that inhibits
3 expression or activity of MASP-2.

1 31. The method of claim 27 in which the compound is
2 a MASP-2 anti-sense nucleic acid sequence.

1 32. The method of claim 30 comprising administering
2 a compound that inhibits complexing of MBL and MASP-2.

1 33. An assay for polymorphisms in the nucleic acid
2 sequence encoding MASP-2.

1 34. A method of detecting the presence of MASP-2-
2 encoding nucleic acid in a sample, comprising mixing the
3 sample with at least one nucleic acid probe capable of
4 forming a complex with MASP-2-encoding nucleic acid under
5 stringent conditions, and determining whether the probe is
6 bound to sample nucleic acid.

1 35. A nucleic acid probe capable of forming a
2 complex with MASP-2-encoding nucleic acid under stringent
3 conditions.

1 36. An assay for polymorphisms in the polypeptide
2 sequence comprising MASP-2 or its precursor.

1 37. A method for diagnosing a disorder associated
2 with aberrant expression of MASP-2, comprising obtaining a
3 biological sample from a patient and measuring MASP-2
4 expression in said biological sample, wherein increased or
5 decreased MASP-2 expression in said biological sample
6 compared to a control indicates that said patient suffers
7 from a disorder associated with aberrant expression of MASP-
8 2.

1 38. A method for diagnosing a disorder associated
2 with aberrant activity of MASP-2, comprising obtaining a
3 biological sample from a patient and measuring MASP-2
4 activity in said biological sample, wherein increased or
5 decreased MASP-2 activity in said biological sample compared
6 to a control indicates that said patient suffers from a
7 disorder associated with aberrant activity of MASP-2.

1 39. A method of assaying for activity MBL-complexed
2 MASP, the method comprising
3 providing a sample to be assayed and substantially
4 reducing any artifact resulting from activation of the
5 classical complement fixing pathway by conducting the assay
6 in the presence of an ionic strength high enough to
7 effectively reduce activation of the classical complement
8 fixing pathway but not so high as to substantially interfere
9 with activity of MBL-complexed MASP.

add
C4

09074238-060401